{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:36:01Z","timestamp":1784896561345,"version":"3.55.0"},"reference-count":94,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NRF-NRFF2013-02"],"award-info":[{"award-number":["NRF-NRFF2013-02"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Cancer cells are highly reliant on certain molecular pathways, which support their survival and proliferation. The fundamental concept of molecularly targeted therapy is to target a protein that is specifically deregulated or overexpressed in cancer cells. However, drug resistance and tumor heterogeneity are major obstacles in the development of specific inhibitors. Additionally, many driver oncogenes exert their oncogenic property via abnormal expression without having genetic mutations. Interestingly, recent accumulating evidence has demonstrated that many critical cancer genes are driven by a unique class of enhancers termed super-enhancers. Genes associated with super-enhancers are relatively more susceptible to the inhibition of general transcriptional machinery compared with genes that are regulated by typical enhancers. Cancer cells are more sensitive to treatment with small-molecule inhibitors of CDK7 or BRD4 than non-transformed cells. These findings proposed a novel strategy to identify functionally important genes as well as novel therapeutic modalities in cancer. This approach would be particularly useful for genetically complicated cancers, such as adult T-cell leukemia (ATL), whereby a large mutational burden is present, but the functional consequences of each mutation have not been well-studied. In this review, we discuss recent findings on super-enhancers, underlying mechanisms, and the efficacy of small-molecule transcriptional inhibitors in ATL.<\/jats:p>","DOI":"10.3390\/molecules23051057","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T03:20:27Z","timestamp":1525317627000},"page":"1057","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia"],"prefix":"10.3390","volume":"23","author":[{"given":"Regina Wan Ju","family":"Wong","sequence":"first","affiliation":[{"name":"Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-0777","authenticated-orcid":false,"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka 020-8505, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1621-4954","authenticated-orcid":false,"given":"Takaomi","family":"Sanda","sequence":"additional","affiliation":[{"name":"Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore"},{"name":"Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore"},{"name":"14 Medical Drive, Centre for Translational Medicine, #12-01, Singapore 117599, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non\u2013Small-Cell Lung Cancer to Gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: Clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes\u2014The Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrc1947","article-title":"Lineage dependency and lineage-survival oncogenes in human cancer","volume":"6","author":"Garraway","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1101\/gad.1609907","article-title":"Oncogene addiction: Setting the stage for molecularly targeted cancer therapy","volume":"21","author":"Sharma","year":"2007","journal-title":"Genes Dev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: Learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1470-2045(11)70335-7","article-title":"Genetic heterogeneity and cancer drug resistance","volume":"13","author":"Turner","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: A looking glass for cancer?","volume":"12","author":"Marusyk","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nature15816","article-title":"Building the foundation for genomics in precision medicine","volume":"526","author":"Aronson","year":"2015","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrg.2016.86","article-title":"Towards precision medicine","volume":"17","author":"Ashley","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional Addiction in Cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Loven","year":"2013","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","article-title":"Targeting transcription regulation in cancer with a covalent CDK7 inhibitor","volume":"511","author":"Kwiatkowski","year":"2014","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","article-title":"Master transcription factors and mediator establish super-enhancers at key cell identity genes","volume":"153","author":"Whyte","year":"2013","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrc.2016.62","article-title":"The role of enhancers in cancer","volume":"16","author":"Sur","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nrg3682","article-title":"Transcriptional enhancers: From properties to genome-wide predictions","volume":"15","author":"Shlyueva","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.molcel.2013.01.038","article-title":"Modification of Enhancer Chromatin: What, How, and Why?","volume":"49","author":"Calo","year":"2013","journal-title":"Mol. Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood-2017-11-737379","article-title":"Enhancer dysfunction in leukemia","volume":"131","author":"Bhagwat","year":"2018","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.278.5340.1059","article-title":"Oncogenic transcription factors in the human acute leukemias","volume":"278","author":"Look","year":"1997","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1126\/science.1259037","article-title":"An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element","volume":"346","author":"Mansour","year":"2014","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature15540","article-title":"Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism","volume":"528","author":"Oldridge","year":"2015","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/leu.2017.75","article-title":"APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL","volume":"31","author":"Li","year":"2017","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"14385","DOI":"10.1038\/ncomms14385","article-title":"Small genomic insertions form enhancers that misregulate oncogenes","volume":"8","author":"Abraham","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT Promoter Mutations in Familial and Sporadic Melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly Recurrent TERT Promoter Mutations in Human Melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The Epigenomics of Cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1038\/sj.onc.1205651","article-title":"DNA methylation in cancer: Too much, but also too little","volume":"21","author":"Ehrlich","year":"2002","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrg3554","article-title":"Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer","volume":"14","author":"Plass","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccr.2012.06.007","article-title":"Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia","volume":"22","author":"Sanda","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1101\/gad.302646.117","article-title":"ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis","volume":"31","author":"Leong","year":"2017","journal-title":"Genes Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrg2641","article-title":"ChIP-seq: Advantages and challenges of a maturing technology","volume":"10","author":"Park","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.cell.2015.08.008","article-title":"Architectural and Functional Commonalities between Enhancers and Promoters","volume":"162","author":"Kim","year":"2015","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","article-title":"Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma","volume":"24","author":"Chapuy","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","article-title":"CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer","volume":"159","author":"Chipumuro","year":"2014","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood-2017-06-792184","article-title":"Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cbpa.2010.03.022","article-title":"A complex task? Direct modulation of transcription factors with small molecules","volume":"14","author":"Koehler","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u2018undruggable\u2019 cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","article-title":"Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4","volume":"19","author":"Yang","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/leu.2013.338","article-title":"Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia","volume":"28","author":"Dawson","year":"2014","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrm.2017.10","article-title":"The code and beyond: Transcription regulation by the RNA polymerase II carboxy-terminal domain","volume":"18","author":"Harlen","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ccell.2014.10.019","article-title":"Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor","volume":"26","author":"Christensen","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/0008-5472.CAN-17-1143","article-title":"Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma","volume":"77","author":"Yuan","year":"2017","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cell.2017.02.007","article-title":"A Phase Separation Model for Transcriptional Control","volume":"169","author":"Hnisz","year":"2017","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrm.2017.7","article-title":"Biomolecular condensates: Organizers of cellular biochemistry","volume":"18","author":"Banani","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2004.05.007","article-title":"Cellular control of gene expression by T-type cyclin\/CDK9 complexes","volume":"337","author":"Garriga","year":"2004","journal-title":"Gene"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"research0041","DOI":"10.1186\/gb-2001-2-10-research0041","article-title":"Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol","volume":"2","author":"Lam","year":"2001","journal-title":"Genome Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1128\/MCB.00595-14","article-title":"Cyclin-Dependent Kinase 7 Controls mRNA Synthesis by Affecting Stability of Preinitiation Complexes, Leading to Altered Gene Expression, Cell Cycle Progression, and Survival of Tumor Cells","volume":"34","author":"Kelso","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrc2111","article-title":"Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation","volume":"7","author":"Matsuoka","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","article-title":"Adult T-cell leukemia: Molecular basis for clonal expansion and transformation of HTLV-1-infected T cells","volume":"129","author":"Watanabe","year":"2017","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ijc.20007","article-title":"Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells","volume":"109","author":"Takeda","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.0507631103","article-title":"HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells","volume":"103","author":"Satou","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1349-7006.1989.tb02289.x","article-title":"Multi-step carcinogenesis model for adult T-cell leukemia","volume":"80","author":"Okamoto","year":"1989","journal-title":"Jpn. J. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3324\/haematol.2010.028605","article-title":"Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia\/lymphoma as a target for epigenetic therapy","volume":"96","author":"Sasaki","year":"2011","journal-title":"Haematologica"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2015-08-662593","article-title":"Polycomb-dependent epigenetic landscape in adult T-cell leukemia","volume":"127","author":"Fujikawa","year":"2016","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/cncr.10480","article-title":"Adult T-cell leukemia\/lymphoma: A cytopathologic, immunocytochemical, and flow cytometric study","volume":"96","author":"Dahmoush","year":"2002","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2004.04999.x","article-title":"Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia\/lymphoma cells","volume":"126","author":"Karube","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/21690","article-title":"The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage","volume":"399","author":"Gong","year":"1999","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/21704","article-title":"p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage","volume":"399","author":"Yuan","year":"1999","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrc861","article-title":"p73: Friend or foe in tumorigenesis","volume":"2","author":"Melino","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_78","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: Its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-04-0983","article-title":"The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia\/lymphoma","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1349-7006.2010.01767.x","article-title":"Immunopathogenesis of lymphoma: Focus on CCR4","volume":"102","author":"Ishida","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cmdc.201700447","article-title":"Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb\/CDK9 Inhibitor for the Treatment of Cancer","volume":"12","author":"Scholz","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/1538-7445.AM2016-3022","article-title":"Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb\/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)","volume":"76","author":"Scholz","year":"2016","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2016-09-741983","article-title":"Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia\/lymphoma","volume":"130","author":"Narita","year":"2017","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/MCB.01365-08","article-title":"Brd4 Coactivates Transcriptional Activation of NF-\u03baB via Specific Binding to Acetylated RelA","volume":"29","author":"Huang","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1038\/sj.onc.1208969","article-title":"Activation of NF-kappaB by HTLV-I and implications for cell transformation","volume":"24","author":"Sun","year":"2005","journal-title":"Oncogene"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1358\/dnp.2006.19.4.985934","article-title":"Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia\/lymphoma","volume":"19","author":"Horie","year":"2006","journal-title":"Drug News Perspect."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ho, Y.-K., Zhi, H., Bowlin, T., Dorjbal, B., Philip, S., Zahoor, M.A., Shih, H.M., Semmes, O.J., Schaefer, B., and Glover, J.N. (2015). HTLV-1 Tax Stimulates Ubiquitin E3 Ligase, Ring Finger Protein 8, to Assemble Lysine 63-Linked Polyubiquitin Chains for TAK1 and IKK Activation. PLOS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005102"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1038\/sj.onc.1207058","article-title":"Segregation of NF-\u03baB activation through NEMO\/IKK\u03b3 by Tax and TNF\u03b1: Implications for stimulus-specific interruption of oncogenic signaling","volume":"22","author":"Iha","year":"2003","journal-title":"Oncogene"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.onc.1202405","article-title":"Gene expression profiles in HTLV-I-immortalized T cells: Deregulated expression of genes involved in apoptosis regulation","volume":"18","author":"Harhaj","year":"1999","journal-title":"Oncogene"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ijc.20954","article-title":"Transcriptional activation of survivin through the NF-\u03baB pathway by human T-cell leukemia virus type I tax","volume":"115","author":"Kawakami","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"36094","DOI":"10.1074\/jbc.M113.485029","article-title":"Bromodomain and Extraterminal (BET) Protein Inhibition Suppresses Human T Cell Leukemia Virus 1 (HTLV-1) Tax Protein-mediated Tumorigenesis by Inhibiting Nuclear Factor \u03baB (NF-\u03baB) Signaling","volume":"288","author":"Wu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.chembiol.2017.11.007","article-title":"Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors","volume":"25","author":"Gao","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/5\/1057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:02:54Z","timestamp":1760194974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/5\/1057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":94,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5]]}},"alternative-id":["molecules23051057"],"URL":"https:\/\/doi.org\/10.3390\/molecules23051057","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]}}}